CorMedix Says DefenCath's 2027 Add-On Will Average More Than 2x Today's $2.37, Holds Revenue Outlook
The company reaffirmed 2026 revenue guidance of $325 million to $345 million and reported about $355 million in cash.
CorMedix, which sells the dialysis catheter treatment DefenCath, reaffirmed its 2026 revenue guidance of $325 million to $345 million on Monday and disputed a large dialysis chain's projections for how DefenCath's 2027 Medicare add-on payment will move each quarter. The company said any such third-party forecast is highly uncertain and should not be read as guidance it endorses.
Pushing back on the dialysis chain
CorMedix said in a business update that it knows of statements a large dialysis organization made on its investor call about the quarterly path of the 2027 add-on. The company said it has not given that organization or anyone else past or forecast utilization or pricing data, the inputs needed to estimate future quarterly adjustments.
CorMedix said it anticipates the add-on will fall in the second quarter of 2027 from the first, then rise in the third and/or fourth quarter, depending on how CMS applies certain utilization data. It believes the rate will exceed the current $2.37 in all four quarters and that the four-quarter average will be more than twice that level.
An $8.32 first-quarter rate
On October 28, CMS released its 2027 final payment rule for dialysis. It set DefenCath's post-TDAPA add-on at $8.32 per session for the first quarter of 2027 and created a new quarterly process for adjusting it. CorMedix said $8.32 sits inside its previously guided range of 3x to 5x the $2.37 rate in effect for the third and fourth quarters of 2026.
Cash and guidance
CorMedix reported unaudited cash and equivalents of about $355 million as of September 30, 2026, and reaffirmed the revenue guidance it gave in August. DefenCath is its main U.S. product and is sold mainly to outpatient dialysis clinics and hospitals; the company also sells infectious disease products it gained with its Melinta Therapeutics purchase, plus the heart drug TOPROL-XL.
The company cautioned that higher reimbursement to dialysis facilities may not translate into higher realized pricing, utilization or revenue for CorMedix.
CorMedix expects to hold its call on November 12 to discuss quarterly results, and said it will give more specifics about a week beforehand.
Sources
- 8-K Filing — CorMedix Inc. (CRMD) — SEC EDGAR
- Exhibit ea031044501ex99-1.htm — CorMedix Inc. 8-K exhibit — SEC EDGAR
- CorMedix Therapeutics Provides Business Update, Reaffirms — globenewswire.com